JMP Securities upgraded shares of Loxo Oncology, Inc. (NASDAQ:LOXO) from a market perform rating to an outperform rating in a research note released on Tuesday morning. JMP Securities currently has $95.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $77.18.

A number of other equities research analysts have also issued reports on the stock. Ifs Securities raised shares of Loxo Oncology from an outperform rating to a strong-buy rating in a report on Tuesday. Citigroup Inc. reissued a buy rating and issued a $112.00 price target (up previously from $86.00) on shares of Loxo Oncology in a report on Friday, October 20th. Morgan Stanley reissued an overweight rating and issued a $103.00 price target (up previously from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. BTIG Research reissued a buy rating and issued a $102.00 price target (up previously from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Finally, Cowen and Company reissued a buy rating on shares of Loxo Oncology in a report on Thursday, September 28th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $91.14.

Shares of Loxo Oncology (NASDAQ:LOXO) traded down $3.39 during trading on Tuesday, reaching $79.84. 2,987,500 shares of the company’s stock were exchanged, compared to its average volume of 364,079. Loxo Oncology has a 1-year low of $25.25 and a 1-year high of $95.92.

TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) Upgraded by JMP Securities to Outperform” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/15/loxo-oncology-inc-loxo-upgraded-by-jmp-securities-to-outperform.html.

In other news, CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $89.02, for a total transaction of $1,335,300.00. Following the sale, the chief executive officer now owns 196,207 shares of the company’s stock, valued at approximately $17,466,347.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lori Anne Kunkel sold 10,000 shares of Loxo Oncology stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $75.17, for a total transaction of $751,700.00. Following the sale, the director now directly owns 16,840 shares in the company, valued at approximately $1,265,862.80. The disclosure for this sale can be found here. Insiders have sold a total of 76,814 shares of company stock worth $6,548,261 in the last ninety days. Insiders own 27.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Loxo Oncology during the 3rd quarter valued at about $2,253,000. Cornerstone Capital Management Holdings LLC. bought a new stake in shares of Loxo Oncology during the 3rd quarter valued at about $847,000. Sectoral Asset Management Inc boosted its stake in shares of Loxo Oncology by 10.6% during the 3rd quarter. Sectoral Asset Management Inc now owns 245,226 shares of the biopharmaceutical company’s stock valued at $22,590,000 after purchasing an additional 23,431 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Loxo Oncology by 3.1% during the 3rd quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock valued at $3,371,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Loxo Oncology by 29.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 105,741 shares of the biopharmaceutical company’s stock valued at $9,741,000 after purchasing an additional 24,025 shares in the last quarter. 99.31% of the stock is currently owned by hedge funds and other institutional investors.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.